Clinical Trial Update: Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating therapeutic plasma exchange in combination with enfortumab vedotin and pembrolizumab for metastatic bladder urothelial carcinoma and ur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma of the Renal Pelvis
• Urothelial Carcinoma of the Ureter

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Padcev (enfortumab vedotin)

Snippet

Sponsor: Mayo Clinic | Conditions: Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma | Phase 2 | Status: RECRUITING